Insulin-like growth factor-I (IGF-I)1 and insulin interact with related receptors to lower plasma glucose and to exert mitogenic effects. Recombinant human IGF-I (rhIGF-I) was recently shown to decrease serum levels of insulin and C-peptide in fasted normal subjects without affecting plasma glucose levels. In this study we have investigated in six healthy volunteers the responses of glucose, insulin, and C-peptide levels to intravenous rhIGF-I infusions (7 and 14 gg/kg-h) during standard oral glucose tolerance tests (oGTT) and meal tolerance tests (MITT), respectively.
Introduction
Insulin-like growth factor-I (IGF-I)' promotes growth and dif-mimics several effects of insulin such as the stimulation ofglucose transport and glycogen synthesis in muscle (2) (3) (4) . While these effects are mostly mediated by the interaction of IGF-I with the type 1 IGF receptor on muscle cells (2) (3) (4) , other important targets of insulin such as adipose tissue (5, 6 ) and liver cells (7) reveal few, if any, type 1 IGF receptors. Here, IGF-I interacts predominantly with insulin receptors (6, 7) .
Recombinant human IGF-I (rhIGF-I), administered in high doses as intravenous bolus or infusion, caused hypoglycemia in animals (8-1 1) and in healthy humans (12) . The hypoglycemic potency ofrhIGF-I was about 12-fold lower than that of insulin (1 1, 12) . RhIGF-I increased glucose uptake of the skeletal muscle in vivo (10, 11, 13) , but was less effective in relation to insulin in the suppression ofhepatic glucose production (10, 11, 13, 14) . Furthermore, rhIGF-I exerts marked anabolic effects in hypophysectomized (15) and in diabetic rats (16) . In fasting human subjects, infusions of rhIGF-I lowered insulin and C-peptide levels (17) as a result ofthe hypoglycemic effect (4, 11, 12) and/or the suppression ofinsulin secretion via type 1 IGF receptors on the (3-cells (18) . RhIGF-I may also increase insulin sensitivity of target tissues through the decrease of glucose and consequently insulin levels and the suppression of growth hormone (GH) secretion (10, 14, 17) .
Insulin resistance is characteristically found in acromegalic patients (19, 20) who have impaired glucose tolerance or frank diabetes in the face of hyperinsulinemia (19, 20) . Prolonged fasting, on the other hand, is accompanied by low insulin levels (21) (22) (23) (24) and impaired glucose tolerance (21) (22) (23) (24) because of a delayed insulin response to hyperglycemia (21) .
RhIGF-I administration has been shown to lower insulin and C-peptide levels in fasted subjects ( 17) . Here, the effects of rhIGF-I infusions on glucose and meal tolerance and (3cell function were investigated, and we have found that glucose and meal tolerance were unaffected by rhIGF-I infusions while insulin and C-peptide levels decreased markedly and dose-dependently.
Methods
Subjects. Six Experimental protocol. The study consisted ofthree periods of 2 d each during which the volunteers received infusions of 7 and 14 1Ag rhIGF-I/kg body wt per h i.v., and saline in a randomized crossover fashion. The volunteers were blinded to the type ofinfusion they were receiving. The three study periods were at least 10 d apart.
During each part ofthe study, the volunteers received a sucrose-free diet of2,400 kcal/d, composed of50% carbohydrates, 30% fat, and 20% protein which were given as breakfast at 8 a.m. (500 kcal), lunch at 1 p.m. (950 kcal), and dinner at 7 p.m. (950 kcal). No snacks were allowed between meals.
For each part of the study, the volunteers arrived at the metabolic unit at 7 a.m. of day 1 after an overnight fast. Before 7.30 a.m., an 18 Gauge Venflon* cannula was inserted in an antecubital vein ofthe left forearm and connected to a portable miniaturized infusion pump (MRS-3@; Disetronic AG, Burgdorf, Switzerland) with a cartridge containing saline or rhIGF-I (kindly supplied by Ciba-Geigy AG, Basel, Switzerland). RhIGF-I, dissolved in saline (10 mg/ml), or saline was infused starting at 8 a.m. ofday 1 until 5 p.m. ofday 2. The volunteers were discharged from the metabolic research unit on the following day (day 3).
On Methods. Blood was drawn into tubes containing sodiumfluoride oxalate, centrifuged within 10 min, and analyzed immediately for glucose. Venous blood was drawn into tubes (SST@; Becton Dickinson, Meylan Cedex, France) for separation of serum. After clot retraction for 30 min at 4VC and centrifugation at 1,550 g for 30 min at 4VC, aliquots of serum were stored at -20'C until assayed for serum levels of insulin, C-peptide, GH, total IGF-I and IGF-II, and "free" IGF-I.
Plasma glucose was determined on a glucose analyzer (Model 2;
Beckman Instruments, Inc., Fullerton, CA). Insulin, C-peptide, and GH were determined using commercially available RlAs (Medipro AG, Teufen, Switzerland). All samples from individual volunteers were analyzed within one assay in duplicates or triplicates at one or two dilutions. The interassay coefficients of variation (CV) were 12.4 and 8.5% for insulin (180 and 680 pmol/liter), 5.8 and 2.1% for C-peptide (280 and 1400 pmol/liter), and 0.65% for GH (320 nmol/liter).
For the analysis of total IGF-I and IGF-1I, 250,ul serum were extracted through Sep-Pak C18 (Waters Associates, Milford, MA) according to the protocol supplied by the manufacturer to dissociate IGF from the insulin-like growth factor binding proteins (IGFBPs). The eluate was dried under a stream of air at 370C, lyophilized, and dissolved in PBS containing 0.2% HSA for the assays ofIGF-I and IGF-II in duplicates at three or four dilutions.
IGF-I was analyzed by the method of Zapf et al. (25) which was modified. The first incubation was omitted and 0.1 ml ofthe sample or rhIGF-I standard, 0.2 ml IGF-I antiserum diluted at 1:1,000, and 0.1 ml '25I-IGF-I were simultaneously added. The samples were incubated for 24 h at 4VC, and antibody-bound '25I-IGF-I was precipitated with 40 Ag of rabbit gamma globulin and 50 Ill of goat anti-rabbit gamma globulin, diluted 1:4 with PBS/0.2% HSA. Within a range from 17 to 130 nmol IGF-I/liter, the results obtained were indistinguishable from those obtained with the originally reported method (mean difference±SD -0.9±2.6%, range -6.8 to +8.5%). The inter-and intraassay CV for the modified method were 5.0 and 2.8%, respectively, and those for the original method 5.2 and 2.2%, respectively. The K.d with the modified method was 30.9 nmol/liter, compared with 11.4 nmol/liter with the original method.
The RIA for total IGF-II was carried out as described (25) . RhIGF-II was used as standard. The inter-and intraassay CV were 9.1 and 6.7%, respectively.
Free IGF-I was separated from IGF bound to IGFBPs by chromatography on a Sephadex G-50 fine column (0.75 X 29 cm, bed volume 14.5 ml, flow rate 2 ml/h), equilibrated with 0.15 M NH4HCOJ0.02% NaN3/0.02% HSA (pH 7.8). Free '251-IGF-I eluted between 40 and 77% bed volume. By analysis with Western ligand blotting (26) we observed no detectable IGFBPs in the range between 52 and 77% bed volume with up to 15-fold higher amounts ofeluate than routinely loaded on a lane (not shown). 100-ul serum samples were, therefore, gel filtrated, and fractions between 52 and 77% bed volume were pooled, lyophilized, dissolved in 1 ml distilled water, and relyophilized. The material was dissolved in 225 ,l PBS for analysis ofIGF-I by RIA in duplicates, as described (8) .
Statistics. The results of this study in a small number of subjects (n = 6) cannot be expected to be normally distributed. Thus, Friedman's rank variance analysis (two tailed) for the overall comparison, and Wilcoxon's matched pairs signed rank test (two tailed) for the pairwise comparison of the results were used (27, 28). Areas under the curve (AUC) and linear regressions were calculated using the trapezoidal rule and the method of least squares, respectively. A P value of less than 0.05 was considered significant.
Results
Serum levels of total IGF-I and IGF-II, and free IGF-I were normal before the start of the infusions, and they remained unaltered during the control infusions with 0.9% saline ( Table   Table I I). In response to the rhIGF-I infusions total and free IGF-I levels were raised within 10 h after the start of the infusions, whereas total IGF-II was decreased. On day 2, IGF-I levels were 3.9 and 4.4 times (total), and 1.8 and 4.1 times (free), respectively, above starting levels during the infusions of 7 and 14 ,g rhIGF-I/kg h, respectively, whereas total IGF-II levels decreased as expected (17) to 50 and 32%, respectively. These IGF levels were reached before the start ofthe oGTT. Furthermore, GH levels on day 2 were decreased during the infusions of 7 and 14 gg rhIGF-I/kg * h compared with control infusions (Table II) . Plasma glucose levels on day 1 ranged between 3.1 and 5.6 mmol/liter (not shown) and were, like the glucose profiles on day 2 (Fig. 1, top) , not affected by the administration ofrhIGF-I. The glycemic peak responses and the AUC for glucose (AUC~gUO) between 8 and 10 a.m. during oGTT were slightly delayed and increased during the rhIGF-I infusions (P > 0.05).
When the AUCguc was calculated for the periods between 8 a.m. and 1 p.m. during oGTT and that between 1 and 5 p.m. during MTT, they were indistinguishable whether or not rhIGF-I was infused (21±2 and 21±2 mmol/liter* h during saline, 21±3 and 21±2 mmol/liter * h during 7 Mg rhIGF-I/kg * h, and 23±3 and 21±2 mmol/liter h during 14Mg rhIGF-I/kg. h, respectively).
Serum levels of insulin and C-peptide were lowered in a dose-dependent fashion already 10 h after the start of the rhIGF-I infusions (P < 0.05, not shown), and also on day 2, in the fasting state as well as during oGTT and MTT (Fig. 1, middle and bottom). The AUCiSuiJ,, and AUCcpvid, decreased proportionately and similarly during oGTT and MTT (Table  III) . As suggested by the decrease of the incremental AUC (iAUC)mis,,n and iAUCcppfi& during the rhIGF-I infusions (not shown), the decrease of the AUCs cannot solely be explained by decreased fasting insulin and C-peptide levels. The decrease of the AUCiu,,fin and iAUCinulin, respectively, during rhIGF-I infusions indicates that less insulin is required to dispose of a glucose load during the infusion of rhIGF-I.
The insulin levels during oGTT and MTT decreased in the volunteers during the infusion of 14Mug rhIGF-I/kg* h as a function of fasting insulin levels during saline infusion (Fig. 2) . The relation was similar with the infusion of 7 Mg rhIGF-I/kg h (r = 0.825, P < 0.05 during oGTT and r = 0.895, P < 0.02 during MTT). The findings indicate that insulin levels are decreased more markedly by rhIGF-I infusions in subjects with high normal than in those with low normal fasting insulin levels.
The insulin/glucose-ratio which can be considered as an index of tissue sensitivity to insulin (29) was decreased in response to rhIGF-I infusions at all time points, both before and during oGTT and MTT, respectively (Fig. 3) . The pairwise analysis revealed significantly decreased ratios at 10 (14 Mug rhIGF-I/kg h vs. saline), 3 (14 Mug rhIGF-I/kg h vs. 7 Mig rhIGF-I/kg-h), and 2 (7 ug rhIGF-I/kg-h vs. saline) time points. In contrast, the C-peptide/insulin-ratio was not affected by rhIGF-I infusions before oGTT and MTT (Fig. 4) . It may be assumed, therefore, that the metabolic clearance of insulin remained unchanged.
Discussion IGF-I mimics many effects of insulin such as stimulating glucose transport in muscle and fat cells and glycogen synthesis in (8) (9) (10) (11) (12) (13) (14) . RhIGF-I administered as an intravenous bolus into animals (8, 9) and humans (12) raised free IGF-I levels and caused hypoglycemia. When compared on a molar basis, the hypoglycemic potency of rhIGF-I is about 12-fold lower than that of insulin (1 1 muscle cells (2, 3) , and far less effective on liver (10, 11) and adipose cells (5, 6) . This difference is explained by the high density oftype 1 IGF receptors on muscle cells (2-4) and their low density or absence on liver and adipose cells (5) (6) (7) . Apparently, the effects of IGF-I are mediated through interaction with the type 1 IGF receptor on muscle cells and cross reaction with insulin receptors on adipocytes and hepatocytes.
In this and earlier studies in humans and animals IGF-I infusions increased total IGF-I levels two-to fivefold (10, 1 1, 17) . Under basal conditions, most of the circulating IGF-I is bound to specific IGFBPs (30) that prevent IGF-I from causing hypoglycemia (8) . When exogenously administered rhIGF-I exceeded the binding capacity of the IGFBPs, serum levels of free IGF-I levels were increased (17, 30) . In our study, free IGF-I levels were even more increased 10 h after starting the rhIGF-I infusion than later on (Table I) , since IGFBPs increase with some delay (26) . Therefore, we assume that the free IGF-I levels caused insulin-like effects that resulted in an unaltered glucose tolerance in the face ofmarkedly decreased insulin and C-peptide levels (Fig. 1) . However, high total IGF-I levels do not always mimic the effects ofinsulin. Total IGF-I levels are raised into the range of the present study in acromegalic patients who are insulin resis- tant, as indicated by glucose intolerance and concomitantly elevated insulin and C-peptide levels (19, 20) . Furthermore, increased GH levels induce IGFBP-3 and the acid-labile subunit of the IGFBP-3 complex (26, (31) (32) (33) (34) , which provide for a high IGF-binding capacity (34) and cause increased insulin levels (19, 20) that suppress IGFBP-1 and -2 production (33). IGF-I in acromegaly is, therefore, mostly bound to the IGFBP-3 complex which is linked to anabolic and growth effects (1) . In contrast, rhIGF-I infusions are known to suppress GH secretion (Table II, -2 (35-38) . While IGFBP-3 levels are virtually unchanged during rhIGF-I infusions (26) , serum levels of IGFBP-1 and -2 with short half lives are increased and carry proportionally larger amounts oftotal IGF-I (30). Thus, during rhIGF-I infusions glucose disposal in peripheral tissues is likely to be increased due to elevated serum levels of free IGF-I and increased levels of IGFBP-1 and -2 that cross the vascular barrier into the interstitial space, as shown in the rat heart (39), and from which IGF-I may dissociate. This may have resulted in slightly, though not significantly lower fasting and preprandial glucose levels and a direct and indirect inhibition ofinsulin and C-peptide secretion (40, 41) . Furthermore, rising insulin levels during oGTT diminish IGFBP-I levels (36, 37) so that more free IGF-I may dissociate during oGTT and MTT and stimulate glucose disposal further (36, 38) , as suggested by the decreased iAUCiuli.J during oGTT and MTT during rhIGF-I administration. These mechanisms explain in part the unchanged glucose tolerance despite decreased insulin levels.
Insulin resistance associated with hyperinsulinemia oftype 2 diabetes and obesity (22, 23, 42, 43) is improved by diet and weight loss through the decrease of insulin levels (42) (43) (44) . Thus, the improved tissue sensitivity to insulin during rhIGF-I infusions may also be due to decreased insulin levels. However, very low insulin levels as a result of prolonged fasting (21) (22) (23) (24) are accompanied by increased GH (22) , a delayed insulin response (21) , and impaired glucose tolerance, i.e., "starvationdiabetes" (21, 22) . In this study, we have noted during oGTT that rhIGF-I infusions slightly retarded insulin and C-peptide responses (Fig. 1) , but the discrete changes did not impair glucose tolerance during the 33 h of the rhIGF-I infusions. Prolonged infusions of higher amounts of rhIGF-I, however, may be diabetogenic. Indeed, an infusion of 16 ,gg rhIGF-I/kg * h in a child with Laron-type dwarfism caused fasting hypoglycemia and, at the same time, glucose intolerance due to the suppression of insulin secretion (45) , whereas the administration of smaller amounts of rhIGF-I for 7 d to healthy volunteers did not cause glucose intolerance (46) . RhIGF-I administration for 5 d to type 2 diabetics on a weight-maintaining diet even improved glucose tolerance (47) . Here, the insulin/glucose-ratio remained decreased throughout the rhIGF-I infusions (Fig. 3) , indicating that tissue sensitivity to insulin remained unaltered.
The suppression of insulin secretion by rhIGF-I has been demonstrated in isolated pancreatic (3-cells (40) , in the perfused rat pancreas (41) , as well as in vivo in this study in normal human subjects (Fig. 1) . It may by itself result in an increased tissue sensitivity to insulin (42) (43) (44) , an interpretation which is supported by a close relation between fasting insulin levels and the difference between the AUCi,,,,&, during the infusion of saline and that during rhIGF-I (Fig. 2) . It implies that rhIGF-I has a more pronounced effect in subjects with high normal than in those with low normal insulin levels.
In conclusion, rhIGF-I administered to healthy men decreased insulin and C-peptide levels but did not change glucose tolerance. RhIGF-I, therefore, improves glucose disposal and may also increase tissue sensitivity to insulin because of decreased insulin levels and suppressed GH secretion. Glucose tolerance may also be maintained despite decreased insulin levels as a result of elevated levels of free IGF-I dissociating from the IGFBPs during oGTT and MTT. Independent ofthe mechanism ofaction, rhIGF-I may become an important therapeutic principle in states associated with insulin resistance such as obesity, type 2 diabetes, severe insulin resistance, and hyperlipidemia.
